Loading
IT
ImmunoCellular Therapeutics, Ltd. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Gengos Andrew, was filed 02 Dec 2015.
ImmunoCellular Therapeutics, Ltd.: what insiders have been doing
This page follows insider dealings at ImmunoCellular Therapeutics, Ltd. as filed with SEC (Form 4). Nothing new has been filed by managers of ImmunoCellular Therapeutics, Ltd. in twelve months, the latest record being from 8 June 2018.
Since 2012, the database holds 10 purchases and 16 sales by insiders of the company.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
56
Thresholds
n/a
Buy Volume
€89,016
10 ops. · all time
Sell Volume
€924,332
16 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2017FY ended December 2017 · cache
Income statement
Net income-12.8M
Last declaration on 8 June 2018
Declarations56 total
120,000 shares0Common StockSEC:0001209191-18-036656:0
3,284 shares@ US$2.05100.0% of flowCommon StockSEC:0001209191-17-009955:0
25,000 shares0Common StockSEC:0001209191-16-108475:0
150,000 shares0Common StockSEC:0001209191-16-108468:0
75,000 shares0Common StockSEC:0001209191-16-108469:0
35,000 shares0Common StockSEC:0001209191-16-108471:0
10,000 shares@ US$0.435Common StockSEC:0001209191-15-083020:0
Canonical exit: 28 Feb 2016 (T+90)
25,000 shares@ US$0.27Common StockSEC:0001209191-15-072696:0
14,674 shares@ US$0.46Common StockSEC:0001209191-15-072696:1
10,326 shares0Common StockSEC:0001209191-15-072696:2
10,326 shares0Common StockSEC:0001209191-15-072696:3
10,000 shares0Common StockSEC:0000899243-15-005203:0
10,000 shares0Common StockSEC:0000899243-15-005201:0
75,000 shares0Common StockSEC:0001209191-15-028984:0
150,000 shares0Common StockSEC:0001209191-15-028986:0
35,000 shares0Common StockSEC:0001209191-15-028988:0
30,000 shares@ US$0.60Common StockSEC:0001209191-15-016911:0
Canonical exit: 19 May 2015 (T+90)
41,333 shares@ US$0.60Common StockSEC:0001209191-15-016908:0
Canonical exit: 19 May 2015 (T+90)
16,667 shares@ US$0.60Common StockSEC:0001209191-15-016905:0
Canonical exit: 19 May 2015 (T+90)
11,000 shares@ US$0.91Common StockSEC:0001209191-14-053971:0
Canonical exit: 19 Nov 2014 (T+90)
10,000 shares@ US$0.8994Common StockSEC:0001209191-14-052429:0
Canonical exit: 12 Nov 2014 (T+90)
25,000 sharesCommon StockSEC:0001181431-13-064512:0
Canonical exit: 23 Mar 2014 (T+90)
100 shares@ US$0.7799Common StockSEC:0001181431-13-064026:0
Canonical exit: 20 Mar 2014 (T+90)
17,900 shares@ US$0.78Common StockSEC:0001181431-13-064026:1
Canonical exit: 20 Mar 2014 (T+90)
27,000 shares@ US$0.7171Common StockSEC:0001181431-13-063318:0
Canonical exit: 18 Mar 2014 (T+90)
25 of 56 declarations
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a biopharmaceutical company focused on developing immunotherapy treatments for cancer. It primarily concentrates on T-cell based therapies and therapeutic vaccines.
